Get the Stockscreener App
4.84
0.21%
-0.010
Abeona Therapeutics Inc stock is traded at $4.84, with a volume of 822.74K.
It is down -0.21% in the last 24 hours and down -8.68% over the past month.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
See More
Previous Close:
$4.85
Open:
$4.87
24h Volume:
822.74K
Relative Volume:
1.75
Market Cap:
$241.56M
Revenue:
-
Net Income/Loss:
$-54.19M
P/E Ratio:
-1.876
EPS:
-2.58
Net Cash Flow:
$-37.34M
1W Performance:
+15.79%
1M Performance:
-8.68%
6M Performance:
-28.19%
1Y Performance:
-38.97%
1-Day Range:
$4.815
$4.955
1-Week Range:
$4.135
$5.02
52-Week Range:
$3.05
$8.17
Abeona Therapeutics Inc Stock (ABEO) Company Profile
Name
Abeona Therapeutics Inc
Sector
Industry
Phone
646-813-4701
Address
6555 CARNEGIE AVE, 4TH FLOOR, CLEVELAND, NY
Compare ABEO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABEO
Abeona Therapeutics Inc
|
4.84 | 241.56M | 0 | -54.19M | -37.34M | -2.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Abeona Therapeutics Inc Stock (ABEO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Oppenheimer | Outperform |
| Jul-03-24 | Initiated | H.C. Wainwright | Buy |
| May-30-24 | Initiated | Stifel | Buy |
| Nov-11-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Feb-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-10-19 | Resumed | Cantor Fitzgerald | Neutral |
| Aug-15-19 | Downgrade | Maxim Group | Buy → Hold |
| Aug-12-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jul-26-19 | Downgrade | Mizuho | Buy → Neutral |
| Jun-27-19 | Initiated | Mizuho | Buy |
| Oct-12-18 | Initiated | Mizuho | Buy |
| Jun-05-18 | Initiated | Seaport Global Securities | Buy |
| Nov-08-17 | Initiated | SunTrust | Buy |
| Oct-16-17 | Reiterated | H.C. Wainwright | Buy |
| Oct-11-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Oct-10-17 | Initiated | Citigroup | Buy |
| Oct-05-17 | Reiterated | Maxim Group | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Jul-18-17 | Reiterated | Maxim Group | Buy |
| Jun-22-17 | Resumed | Jefferies | Buy |
| Jan-06-17 | Initiated | Jefferies | Buy |
| Sep-29-16 | Reiterated | Maxim Group | Buy |
View All
Abeona Therapeutics Inc Stock (ABEO) Latest News
Wellington Management Group LLP Acquires Shares of 93,289 Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
Abeona Therapeutics: An Uncertain Pivotal Regulatory Catalyst With Limited Long-Term Upside - Seeking Alpha
Trexquant Investment LP Invests $382,000 in Abeona Therapeutics Inc (NASDAQ:ABEO) - Defense World
FDA Action Alert: Regeneron, Sanofi and Abeona - BioSpace
Abeona Therapeutics: A Buy With Major PDUFA Catalyst On April 29 That Should Send Shares Higher - Seeking Alpha
Abeona Therapeutics Inc. Rings the Nasdaq Stock Market Closing Bell - Nasdaq
Abeona Therapeutics Inc. Rings the Closing Bell - Nasdaq
Stifel initiates Abeona Therapeutics stock with buy, $14 target By Investing.com - Investing.com UK
(ABEO) Technical Data - news.stocktradersdaily.com
Breakeven On The Horizon For Abeona Therapeutics Inc. (NASDAQ:ABEO) - simplywall.st
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Abeona Therapeutics Expands Team with Strategic Stock Grants for Key New Talent - Stock Titan
Abeona Therapeutics CEO sells shares worth $119,500 By Investing.com - Investing.com India
Abeona Therapeutics CEO sells shares worth $119,500 - Investing.com
What is Zacks Small Cap’s Estimate for ABEO Q3 Earnings? - Defense World
What is Zacks Small Cap’s Forecast for ABEO Q1 Earnings? - Defense World
Equities Analysts Set Expectations for ABEO Q1 Earnings - Defense World
Trend Tracker for (ABEO) - news.stocktradersdaily.com
What is HC Wainwright’s Forecast for ABEO Q1 Earnings? - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Upgraded to “Hold” at StockNews.com - The AM Reporter
Abeona Therapeutics (NASDAQ:ABEO) Given Buy Rating at HC Wainwright - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Upgraded to Hold at StockNews.com - Defense World
Abeona Therapeutics: Positive Outlook Amid FDA Hopes - MSN
ABEO: Countdown to PDUFA Date of April 29, 2025… - MSN
ABEO: Countdown to PDUFA Date of April 29, 2025 - Smartkarma
Abeona Therapeutics Inc. (NASDAQ:ABEO) Q4 2024 Earnings Call Transcript - Insider Monkey
Abeona planning potential US launch of pz-cel to treat RDEB - Epidermolysis Bullosa News
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... - Yahoo
Abeona Therapeutics Inc (ABEO) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... By GuruFocus - Investing.com Canada
Abeona Therapeutics Reports 2024 Financial Results - TipRanks
Earnings call transcript: Abeona Therapeutics reports Q4 2024 EPS beat - Investing.com India
Earnings call transcript: Abeona Therapeutics reports Q4 2024 EPS beat By Investing.com - Investing.com UK
Abeona Therapeutics targets $2B revenue potential for pz-cel amid U.S. launch preparations - MSN
Oppenheimer maintains Abeona Therapeutics Outperform rating - Investing.com India
Abeona Therapeutics® Reports Full Year 2024 Financial - GlobeNewswire
Abeona Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ABEONA THERAPEUTICS INC. SEC 10-K Report - TradingView
Abeona Therapeutics® Reports Full Year 2024 Financial Results, Provides Pz-cel Regulatory - Bluefield Daily Telegraph
Abeona Strengthens to $98M Cash Position as FDA Decision for Pz-cel Approaches - StockTitan
(ABEO) On The My Stocks Page - news.stocktradersdaily.com
Abeona Therapeutics Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Dystrophic Epidermolysis Bullosa Market Forecasted to Surge - openPR.com
Abeona Therapeutics at Leerink’s Global Healthcare Conference: Launch Plans for PZcell - Investing.com Canada
Abeona Therapeutics (ABEO) Projected to Post Earnings on Monday - Defense World
Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated at Oppenheimer - Defense World
Oppenheimer Initiates Coverage of Abeona Therapeutics (ABEO) with Outperform Recommendation - MSN
This Krystal Biotech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Oppenheimer Initiates Coverage of Abeona Therapeutics (LSE:0H7R) with Outperform Recommendation - Nasdaq
Trading (ABEO) With Integrated Risk Controls - Stock Traders Daily
Abeona Therapeutics® to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire
When Abeona Therapeutics Takes the Stage: CEO's Upcoming Leerink Conference Presentation - StockTitan
Abeona Therapeutics Inc Stock (ABEO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):